# EDGAR Filing Document

**Accession Number:** 0001651407
**File Stem:** 0001104659-25-057621
**Filing Date:** 2025-6
**Character Count:** 2776
**Document Hash:** e0bb01c722f009696bff55491c78e120
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-057621.hdr.sgml**: 20250609

**ACCESSION NUMBER**: 0001104659-25-057621

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250609

**DATE AS OF CHANGE**: 20250609

**EFFECTIVENESS DATE**: 20250609

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Checkpoint Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001651407
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 472568632
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38128
- **FILM NUMBER:** 251032874

**BUSINESS ADDRESS:**
- **STREET 1:** 95 SAWYER ROAD
- **STREET 2:** SUITE 110
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453
- **BUSINESS PHONE:** 781-652-4500

**MAIL ADDRESS:**
- **STREET 1:** 95 SAWYER ROAD
- **STREET 2:** SUITE 110
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER<br> SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION<br> OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE<br> SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number 001-38128

**CHECKPOINT THERAPEUTICS, INC.** 

(Exact name of registrant as specified in its charter)

**2 Independence Way**

**Princeton, New Jersey 08540<br> (781) 652-4500**<br> (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Common Stock, par value $0.0001 per share**

(Title of each class of securities covered by this Form)

**None**

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | x |
| Rule 12g-4(a)(2) | ◻ |
| Rule 12h-3(b)(1)(i) | ⌧ |
| Rule 12h-3(b)(1)(ii) | ◻ |
| Rule 15d-6 | ◻ |
| Rule 15d-22(b) | ◻ |

---

Approximate number of holders of record as of the certification or notice date: one (1).

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, Checkpoint Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
| Date: June 9, 2025 | **CHECKPOINT THERAPEUTICS, INC.** | **CHECKPOINT THERAPEUTICS, INC.** |
|  | By: | /s/ Erik Zwicker |
|  | Name: | Erik Zwicker |
|  | Title: | Secretary |

---